CEO Joseph Chee stated, “It’s encouraging to receive support from Solana ecosystem stakeholders, including staking providers, DeFi protocols, and other investors, for our strategy.” 

Funding and Strategy Details 

Helius Medical’s Solana purchase followed a $1.25 billion funding round announced last week. The round included a $750 million private sale managed by Pantera Capital and Summer Capital, as well as potential PIPE proceeds exceeding $500 million. 

Cosmo Jiang, partner at Pantera Capital and observer on Helius’ board, said: “Making the initial accumulation at a lower cost while preserving most of the raised capital shows the team’s market awareness and commitment to maximizing shareholder value.” 

Helius Medical plans to continue acquiring SOL over a 12–24 month period. Tokens will be deployed in decentralized finance solutions and staking activities. The company holds over $335 million in cash reserves for its digital asset strategy. 

Market Reaction and SOL Price 

Despite Helius Medical’s $167 million Solana purchase, SOL fell more than 6% on Monday, trading at $220. Weekly losses reached 7%. Helius shares closed the day at $20 on Nasdaq, down 14%. 

Pantera Capital founder Dan Morehead previously noted that the firm holds $1.1 billion in SOL, making it the largest position. He also highlighted that Solana has outperformed Bitcoin over the last four years. 

Helius Medical’s Solana Objectives: 

• Strengthen total SOL treasury holdings 
• Deploy tokens in DeFi and staking 
• Monitor the market for strategic investment opportunities 

Helius Medical’s move demonstrates growing confidence in Solana and reflects an increasing trend of healthcare companies entering the digital asset space. 

You can also freely share your thoughts and comments about the topic in the comment section. Additionally, don’t forget to follow us on our Telegram, YouTube, and Twitter channels for the latest news and updates.

The post Helius Medical Spends $167M on Solana (SOL) Despite Price Drop appeared first on Coin Engineer.